clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИclinvest-9Research ArticleФАРМАКОЭКОНОМИКАPHARMACOECONOMICSФармакоэкономический анализ применения препарата Мовалис у больных с остеоартрозом и ревматоидным артритомPharmacoeconomic analysis of Movalis in patients with osteoarthritis and rheumatoid arthritisЦветковаЕ. С.TsvetkovaE. S.noemail@neicon.ruБелоусовД. Ю.BelousovD. Yu.clinvest@mail.ruАфанасьеваЕ. В.AfanasyevaE. V.noemail@neicon.ruЛаборатория клинических исследований и международных связей Института ревматологии РАНРоссияLaboratory of Clinical Research and International Relations «Institute of Rheumatology» RASRussian FederationООО "Центр фармакоэкономических исследований", г. МоскваРоссияLLC "Center for Pharmacoeconomics Research", MoscowRussian FederationООО "Центр фармакоэкономических исследований", г. МоскваРоссияLLC "Center for Pharmacoeconomics Research", MoscowRussian Federation201516052018016676Copyright © Цветкова Е.С., Белоусов Д.Ю., Афанасьева Е.В., 20182018Цветкова Е.С., Белоусов Д.Ю., Афанасьева Е.В.Tsvetkova E.S., Belousov D.Y., Afanasyeva E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/9

Objective: To conduct a comparative cost minimization analysis (CMA) of Movalis with other non-steroidal antiinflammatory drugs (NSAIDs) such as diclofenac, nimesulide, celecoxib and etoricoxib. Methodology: Was conducted search of publications from 1990 to 2014, devoted to randomized controlled clinical trials, a network meta-analysis and systematic reviews (level of evidence: AI) use of NSAIDs in patients with osteoarthritis (OA) and rheumatoid arthritis (RA). The model evaluates economical effectiveness of drugs and the comparison is based on the results of the randomized controlled clinical trials (RCCT), network meta-analyzes and systematic reviews. Since the data RCCT, network meta-analyzes and systematic reviews have shown equal efficacy of NSAIDs, model is a particular drug and CMA consists of one line therapy, providing short-term economic evaluation and impact on the health of patients with OA and RA. Results: The results of used of NSAIDs CMA and treatment of complications in patients with OA and RA showed that the total cost of the Movalis (meloxicam) is lower than another drugs: Voltaren (diclofenac), Nimesil (nimesulide), Celebrex (celecoxib) and Arcoxia (etoricoxib). Costs saving for one patient is favor for Movalis in comparison with the Voltaren was 465 rubles (-8.55%), Celebrex - 1.255 rubles (-23.09%), Arcoxia - 1.274 rubles (-23.43%) for a 1 month of therapy. Sub-analysis of the Movalis compared with the Nimesil (nimesulide) for 15 days of therapy showed that the cost savings per patient is favor for meloxicam will be 1.504 rubles (-117.74%). Sensitivity analysis confirmed these findings: an increase in drug prices Movalis by 25% and reducing the price of the reference drugs by 25%, minimizing the cost figures do not go beyond the parameters of the Movalis that demonstrates the stability of the obtained data in the study.

фармакоэкономикаанализ минимизации затратнестероидные противовоспалительные препаратыостеоартрозревматоидный артритмелоксикамдиклофенакнимесулидцелекоксибэторикоксибpharmacoeconomicscost minimization analysisnonsteroidal anti-inflammatory drugsosteoarthritisrheumatoid arthritismeloxicamdiclofenacnimesulidecelecoxibetoricoxibНастоящий экономический анализ был профинансирован фармацевтической компанией «Берингер Ингельхайм», однако это не оказало влияние на результаты данного исследования.ReferencesAndersohn F., Schade R., Suissa S., Garbe E. Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs and the Risk of Ischemic Stroke. // Stroke. 2006;37:1725-1730.Andersohn F., Schade R., Suissa S., Garbe E. Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs and the Risk of Ischemic Stroke. // Stroke. 2006;37:1725-1730.Antonov K.I.M., Isacson D.G.L. Prescription and non-prescription analgesic use in Sweden. Ann Pharmacoter 1998;32:485-94.Antonov K.I.M., Isacson D.G.L. Prescription and non-prescription analgesic use in Sweden. Ann Pharmacoter 1998;32:485-94.Arja Helin-Salmivaara, Arja Virtanen, Risto Vesalainen, Juha M. Gro?nroos, Timo Klaukka, Juhana E. Ida?npa?a?n-Heikkila?, and Risto Huupponen. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. // European Heart Journal (2006) 27, 1657-1663.Arja Helin-Salmivaara, Arja Virtanen, Risto Vesalainen, Juha M. Gro?nroos, Timo Klaukka, Juhana E. Ida?npa?a?n-Heikkila?, and Risto Huupponen. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. // European Heart Journal (2006) 27, 1657-1663.Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. // Gut 1987;28:527-32.Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. // Gut 1987;28:527-32.Blower A.L., Brooks A., Fenn G.C. et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. // Aliment Pharmacol Ther 1997;11:283-91.Blower A.L., Brooks A., Fenn G.C. et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. // Aliment Pharmacol Ther 1997;11:283-91.Caputi A.P., Kong S.X. Concomitant use of gastroprotective agents among users of nonsteroidal anti-inflammatory drugs in Italy. The 14th EULAR Congress. Prague, 13-16 June, 2001.Caputi A.P., Kong S.X. Concomitant use of gastroprotective agents among users of nonsteroidal anti-inflammatory drugs in Italy. The 14th EULAR Congress. Prague, 13-16 June, 2001.Chang C., Shau W., Kuo C., Chen S., Lai M. Increased Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs: A Nationwide Case-Crossover Study. // Stroke. 2010;41:1884-1890.Chang C., Shau W., Kuo C., Chen S., Lai M. Increased Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs: A Nationwide Case-Crossover Study. // Stroke. 2010;41:1884-1890.Chen Y.F., Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteorthritis and rheumatoid arthritis: a systematic review and economic evaluation. // Health Technology Assessment 2008;12:11.Chen Y.F., Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteorthritis and rheumatoid arthritis: a systematic review and economic evaluation. // Health Technology Assessment 2008;12:11.Cockel R. NSAIDs - should every prescription carry a government health warning? // Gut 1987;28:515-8.Cockel R. NSAIDs - should every prescription carry a government health warning? // Gut 1987;28:515-8.Cohen Y., Freeman N.L., Kong S.X. et al. Gastrointestinal health care resource use and costs associated with nonsteroidal anti-inflammatory drugs: analysis of a population cohort in Israel. The 14th EULAR Congress. Prague, 13-16 June, 2001.Cohen Y., Freeman N.L., Kong S.X. et al. Gastrointestinal health care resource use and costs associated with nonsteroidal anti-inflammatory drugs: analysis of a population cohort in Israel. The 14th EULAR Congress. Prague, 13-16 June, 2001.Colberg K., Hettich M., Sigmund R. et al. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. // Curr Med Res Opin 1996;13:363-77.Colberg K., Hettich M., Sigmund R. et al. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. // Curr Med Res Opin 1996;13:363-77.de Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. // Scand J Rheumatol 1992;96(Suppl.):49-53.de Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. // Scand J Rheumatol 1992;96(Suppl.):49-53.Degner F., Lanes S., van Ryn J. et al. Pharmacological and clinical profile meloacam. Therapeutic roles of selective COX-2 inhibitors. Vane J.R., Botting RM. (Eds). London: William Harvey Press, 2001.Degner F., Lanes S., van Ryn J. et al. Pharmacological and clinical profile meloacam. Therapeutic roles of selective COX-2 inhibitors. Vane J.R., Botting RM. (Eds). London: William Harvey Press, 2001.Del Tacca M., Colucci R., Fornai M. et al. Efficacy and tolerability of meloxicam, COX-2 preferential nonsteroidal anti-inflammatory drug. // Clin Drug Ivest 2002;22(12):799-818.Del Tacca M., Colucci R., Fornai M. et al. Efficacy and tolerability of meloxicam, COX-2 preferential nonsteroidal anti-inflammatory drug. // Clin Drug Ivest 2002;22(12):799-818.Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. // Brit J Rheumatol 1998;37(9):946-51.Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. // Brit J Rheumatol 1998;37(9):946-51.Elliott A.M., Smith B.H., Penny K.L. et al. The epidemiology of chronic pain in the community. // Lancet 1999;354:1248-52.Elliott A.M., Smith B.H., Penny K.L. et al. The epidemiology of chronic pain in the community. // Lancet 1999;354:1248-52.Fries J.F. NSAID gastropathy: the second most deadly theumatic disease? Epidemiology and risk appraisal. // J Rheumatol 1991;28(Suppl.):6-10.Fries J.F. NSAID gastropathy: the second most deadly theumatic disease? Epidemiology and risk appraisal. // J Rheumatol 1991;28(Suppl.):6-10.Hawkey C. et al. Gastrointestinal tolerability of meloxicam compared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. // Rheumatol (Oxford) 1999;38:793-8.Hawkey C. et al. Gastrointestinal tolerability of meloxicam compared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. // Rheumatol (Oxford) 1999;38:793-8.Hogan D.B., Campbell N.R. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. // Can Med Assoc J 1994;151:315-22.Hogan D.B., Campbell N.R. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. // Can Med Assoc J 1994;151:315-22.Hurley J., Mucha L., Straus W. et al. NSAID and concomitant gastrointestinal drug use among cases and controls in a managed care population. // Gastroenterology 2000;118(Suppl.):A3914.Hurley J., Mucha L., Straus W. et al. NSAID and concomitant gastrointestinal drug use among cases and controls in a managed care population. // Gastroenterology 2000;118(Suppl.):A3914.Jansen R.B., Capri S., Nuijten M.J.C. Economic evaluation of meloxicam (7,5 mg) versus sustained release diclofenac (100 mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK. // Brit J Med Econom 1997;11:9-22.Jansen R.B., Capri S., Nuijten M.J.C. Economic evaluation of meloxicam (7,5 mg) versus sustained release diclofenac (100 mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK. // Brit J Med Econom 1997;11:9-22.Hawkey C., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. // Brit J Rheumatol 1998;37(9):937-45.Hawkey C., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. // Brit J Rheumatol 1998;37(9):937-45.Kephart G., Sketris I., Smith M. et al. Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia’s senior population. // Clin Ther 1995;17:1159-73.Kephart G., Sketris I., Smith M. et al. Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia’s senior population. // Clin Ther 1995;17:1159-73.Knill-Jones R.P. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary of article by G. de Pouvourville. // Scand J Rheumatol 1992;96(Suppl.):59-62.Knill-Jones R.P. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary of article by G. de Pouvourville. // Scand J Rheumatol 1992;96(Suppl.):59-62.Laine L., Goldkind L., Curtis S.P., Connors L.G., et al. How Common Is Diclofenac-Associated Liver Injury? Analysis of17,289 Arthritis Patients in a Long-Term Prospective Clinical Trial. // The American Journal of gastroenterology. 2009, VOLUME 104, pp. 356-362.Laine L., Goldkind L., Curtis S.P., Connors L.G., et al. How Common Is Diclofenac-Associated Liver Injury? Analysis of17,289 Arthritis Patients in a Long-Term Prospective Clinical Trial. // The American Journal of gastroenterology. 2009, VOLUME 104, pp. 356-362.Langman M.J., Kahler K.H., Kong S.X. et al. Use of gastroprotective agents and other healthcare resources among patients on nonsteroidal anti-inflammatory drugs in the United Kingdom. The 12th EULAR Congress. Glasgow, 6-11 June, 1999.Langman M.J., Kahler K.H., Kong S.X. et al. Use of gastroprotective agents and other healthcare resources among patients on nonsteroidal anti-inflammatory drugs in the United Kingdom. The 12th EULAR Congress. Glasgow, 6-11 June, 1999.Laporte J., Ibanez L., Vadal X., Vendrell L., Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs. // Drug safety, 2004; 27 (6): 411-420.Laporte J., Ibanez L., Vadal X., Vendrell L., Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs. // Drug safety, 2004; 27 (6): 411-420.Mangoni A.A., Woodman R.J., Ganis P., Gilbert A.L., Knights K.M. Use of non-steroidal anti-inflammatory drugs and risk of incident miocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. // British Journal of Clinical Pharmacology, 2010, 69:6, pp. 689-700.Mangoni A.A., Woodman R.J., Ganis P., Gilbert A.L., Knights K.M. Use of non-steroidal anti-inflammatory drugs and risk of incident miocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. // British Journal of Clinical Pharmacology, 2010, 69:6, pp. 689-700.Moore N., Montout C. Use of gastrointestinal protective agents among patients on nonsteroidal anti-inflammatory drugs in France and prevention of treatment of adverse GI effects. 12th EULAR Congress. Glasgow, 6-11 June, 1999.Moore N., Montout C. Use of gastrointestinal protective agents among patients on nonsteroidal anti-inflammatory drugs in France and prevention of treatment of adverse GI effects. 12th EULAR Congress. Glasgow, 6-11 June, 1999.Moore N., Verschuren X., Montout C. et al. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. // Therapie 2000;55:133-6.Moore N., Verschuren X., Montout C. et al. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. // Therapie 2000;55:133-6.Moore R.A. The hidden costs of arthritis treatment and the cost of new therapy - the burden of non-steroidal anti-inflammatory drug gastropathy. // Rheumatology (Oxford) 2002;41(Suppl.1):7-15.Moore R.A. The hidden costs of arthritis treatment and the cost of new therapy - the burden of non-steroidal anti-inflammatory drug gastropathy. // Rheumatology (Oxford) 2002;41(Suppl.1):7-15.Moore R.A., Phillips C.J. Cost of NSAID adverse effects to the UK National Health Service. // J Med Econ 1999;156:2321-32.Moore R.A., Phillips C.J. Cost of NSAID adverse effects to the UK National Health Service. // J Med Econ 1999;156:2321-32.Pfizer. Celecoxib Study 096 (SUCCESS-1). 2004 submission (commercial-in-confidence). 2004.Pfizer. Celecoxib Study 096 (SUCCESS-1). 2004 submission (commercial-in-confidence). 2004.Rahme E., Joseph L., Kong S.X. et al. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. // Br J Clin Pharmacol 2001;52:185-92.Rahme E., Joseph L., Kong S.X. et al. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. // Br J Clin Pharmacol 2001;52:185-92.Rostom A., Goldkind L., Lain L. Nonsteroidal anti-inflammatory drugs and hepatic toxity: a systematic review of randomized controlled trials in arthritis patients. // Clin Gastroenterol Hepatol. 2005, 3:5, pp. 489-498.Rostom A., Goldkind L., Lain L. Nonsteroidal anti-inflammatory drugs and hepatic toxity: a systematic review of randomized controlled trials in arthritis patients. // Clin Gastroenterol Hepatol. 2005, 3:5, pp. 489-498.Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. // JAMA 2000;284:1247-55.Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. // JAMA 2000;284:1247-55.Singh G. Recent considerations in nonsteroidal anti-inflammatory gastropathy. // Am J Med 1998;105:31S-38S.Singh G. Recent considerations in nonsteroidal anti-inflammatory gastropathy. // Am J Med 1998;105:31S-38S.Singh G., Lanes S., Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. // American journal of medicine, 2004, Volume 117, pp.100-106.Singh G., Lanes S., Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. // American journal of medicine, 2004, Volume 117, pp.100-106.Singh G., Ramey D.R. Gastrointestinal tract complications on nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. // Arch Inern Med 1996;156:1530-6.Singh G., Ramey D.R. Gastrointestinal tract complications on nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. // Arch Inern Med 1996;156:1530-6.Tavakoli M. Modelling Therapeutic Strategies in the Treatment of Osteoarthritis: An Economic Evaluation of Meloxicam Versus Diclofenac and Piroxicam. // Pharmacoeconomics 2003;21(6):443-54.Tavakoli M. Modelling Therapeutic Strategies in the Treatment of Osteoarthritis: An Economic Evaluation of Meloxicam Versus Diclofenac and Piroxicam. // Pharmacoeconomics 2003;21(6):443-54.Trelle S., Reichenbach S., Wandel S., Hildebrand P., Tschannen B., Villinger P. V., Egger M., Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. // British Medical Journal, 2011, 342, pp.7086.Trelle S., Reichenbach S., Wandel S., Hildebrand P., Tschannen B., Villinger P. V., Egger M., Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. // British Medical Journal, 2011, 342, pp.7086.Аналитическая информация, IMS Россия, январь 2013 г. - сентябрь 2014 г. [Электронный ресурс]. URL:http://www.ims.ru/.Аналитическая информация, IMS Россия, январь 2013 г. - сентябрь 2014 г. [Электронный ресурс]. URL:http://www.ims.ru/.Насонова В.А., Воробьёв П.А., Цветкова ЕС. и др. Фармакоэкономический анализ применения двух нестероидных противовоспалительных препаратов в ревматологии. // Науч-практич ревматол 2002;1:63-8.Насонова В.А., Воробьёв П.А., Цветкова ЕС. и др. Фармакоэкономический анализ применения двух нестероидных противовоспалительных препаратов в ревматологии. // Науч-практич ревматол 2002;1:63-8.Отраслевой стандарт «Клинико-экономические исследования. Общие положения» Приказ Минздрава РФ от 27.05.2002 №163 вместе с ост 91500.14.0001-2002 [Электронный ресурс]. http://www.healtheconomics.ru/index.php?option=com_content&view=artide&id=300:-q-q&catid=55:2009-05-29-19-56-44&Itemid=104.Отраслевой стандарт «Клинико-экономические исследования. Общие положения» Приказ Минздрава РФ от 27.05.2002 №163 вместе с ост 91500.14.0001-2002 [Электронный ресурс]. http://www.healtheconomics.ru/index.php?option=com_content&view=artide&id=300:-q-q&catid=55:2009-05-29-19-56-44&Itemid=104.Ревматология: клинические рекомендации. // Под ред. акад. РАМН Е.Л. Насонова. - 2-е изд., испр. и доп. - М.: ГЭТОТАР-медиа, 2010 - 752 с.Ревматология: клинические рекомендации. // Под ред. акад. РАМН Е.Л. Насонова. - 2-е изд., испр. и доп. - М.: ГЭТОТАР-медиа, 2010 - 752 с.Стандарт специализированной медицинской помощи при других заболеваниях печени, №772н.Стандарт специализированной медицинской помощи при других заболеваниях печени, №772н.Стандарт специализированной медицинской помощи при инфаркте мозга, №1740н.Стандарт специализированной медицинской помощи при инфаркте мозга, №1740н.Стандарт специализированной медицинской помощи при остром инфаркте миокарда с подьёмом сегмента ST электрокардиограммы, №907н.Стандарт специализированной медицинской помощи при остром инфаркте миокарда с подьёмом сегмента ST электрокардиограммы, №907н.Стандарт специализированной медицинской помощи при субарахноидальных, внутримозговых и неуточнённых кровоизлияниях, №1791н.Стандарт специализированной медицинской помощи при субарахноидальных, внутримозговых и неуточнённых кровоизлияниях, №1791н.Стандарт специализированной медицинской помощи при язвенной болезни желудка, двенадцатиперстной кишки, №773н.Стандарт специализированной медицинской помощи при язвенной болезни желудка, двенадцатиперстной кишки, №773н.Тарифы на медицинские услуги Московского городского фонда ОМС, введённые в действие с 01.04.2014 г. [Электронный ресурс]. http://www.mgfoms.ru.Тарифы на медицинские услуги Московского городского фонда ОМС, введённые в действие с 01.04.2014 г. [Электронный ресурс]. http://www.mgfoms.ru.Шостак Н.А., Правдюк Н.Г., Клименко А.А., Кондрашов А.А. Болевой синдром в ревматологии. // Медицинский совет, №1, 2013 г., стр. 82-88.Шостак Н.А., Правдюк Н.Г., Клименко А.А., Кондрашов А.А. Болевой синдром в ревматологии. // Медицинский совет, №1, 2013 г., стр. 82-88.Ягудина Р.И., Куликов А.Ю., Серпик В.Г. Дисконтирование при проведении фармакоэкономических исследований. // Фармакоэкономика. 2009; №4: c.10-13.Ягудина Р.И., Куликов А.Ю., Серпик В.Г. Дисконтирование при проведении фармакоэкономических исследований. // Фармакоэкономика. 2009; №4: c.10-13.Tramer M.R., Moore R.A., Reynolds D.J.M., et al. Qualitative estimation of rare adverse events which follow a biological pregression: a new model applied to chronic NSAID use. // Pain 2000;85:169-82.Tramer M.R., Moore R.A., Reynolds D.J.M., et al. Qualitative estimation of rare adverse events which follow a biological pregression: a new model applied to chronic NSAID use. // Pain 2000;85:169-82.

The authors declare that there are no conflicts of interest present.